Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew M Blumenfeld

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Headache|July 3, 2024
Situational prevention: Pharmacotherapy during periods of increased risk for migraine attacksRichard B Lipton, Jessica Ailani, Kathleen Mullin, et al.
Headache|March 22, 2021
Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysisAndrew M Blumenfeld, Peter J Goadsby, David W Dodick, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 12, 2019
Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxietyAndrew M Blumenfeld, Stewart J Tepper, Lawrence D Robbins, et al.
The Journal of Headache and Pain|February 3, 2019
Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL StudyWilliam B Young, J Ivan Lopez, John F Rothrock, et al.
The Journal of Headache and Pain|January 24, 2019
Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL studyWilliam B Young, J Ivan Lopez, John F Rothrock, et al.
Journal of Managed Care & Specialty Pharmacy|September 30, 2023
Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodiesTodd J Schwedt, Jae Lee, Kerry Knievel, et al.
Pain and Therapy|September 17, 2024
Real-World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart ReviewAndrew M Blumenfeld, Laszlo Mechtler, Lisa Cook, et al.
Headache|October 3, 2020
No "Wearing-Off Effect" Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long-Term StudyAndrew M Blumenfeld, Darko M Stevanovic, Mario Ortega, et al.
Neurology and Therapy|August 5, 2023
Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative ReviewAndrew M Blumenfeld, Richard B Lipton, Stephen Silberstein, et al.
Drug Safety|May 19, 2019
Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL StudyPaul K Winner, Andrew M Blumenfeld, Eric J Eross, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Headache|July 3, 2024
Situational prevention: Pharmacotherapy during periods of increased risk for migraine attacksRichard B Lipton, Jessica Ailani, Kathleen Mullin, et al.
Headache|March 22, 2021
Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysisAndrew M Blumenfeld, Peter J Goadsby, David W Dodick, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 12, 2019
Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxietyAndrew M Blumenfeld, Stewart J Tepper, Lawrence D Robbins, et al.
The Journal of Headache and Pain|February 3, 2019
Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL StudyWilliam B Young, J Ivan Lopez, John F Rothrock, et al.
The Journal of Headache and Pain|January 24, 2019
Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL studyWilliam B Young, J Ivan Lopez, John F Rothrock, et al.
Journal of Managed Care & Specialty Pharmacy|September 30, 2023
Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodiesTodd J Schwedt, Jae Lee, Kerry Knievel, et al.
Pain and Therapy|September 17, 2024
Real-World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart ReviewAndrew M Blumenfeld, Laszlo Mechtler, Lisa Cook, et al.
Headache|October 3, 2020
No "Wearing-Off Effect" Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long-Term StudyAndrew M Blumenfeld, Darko M Stevanovic, Mario Ortega, et al.
Neurology and Therapy|August 5, 2023
Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative ReviewAndrew M Blumenfeld, Richard B Lipton, Stephen Silberstein, et al.
Drug Safety|May 19, 2019
Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL StudyPaul K Winner, Andrew M Blumenfeld, Eric J Eross, et al.
Pageof 5